BIM deletion polymorphisms in hispanic patients with non-small cell lung cancer carriers of EGFR mutations

Vista sencilla de ítem
dc.contributor.authorCardona-Mendoza, Andrés Felipe
dc.contributor.authorRojas Puentes, Leonardo
dc.contributor.authorWills, Beatriz
dc.contributor.authorArrieta, Oscar
dc.contributor.authorCarranza Isaza, Hernán
dc.contributor.authorVargas Báez, Carlos Alberto
dc.contributor.authorOtero, Jorge
dc.contributor.authorCorrales-Rodriguez, Luis
dc.contributor.authorMartín, Claudio
dc.contributor.authorReguart, Noemi
dc.contributor.authorArchila, Pilar
dc.contributor.authorRodríguez Ariza, July Katherine
dc.contributor.authorCuello, Mauricio
dc.contributor.authorOrtíz, Carlos
dc.contributor.authorFranco, Sandra
dc.contributor.authorRolfo, Christian
dc.contributor.authorRosell, Rafael
dc.contributor.orcidCardona-Mendoza, Andrés Felipe [0000-0002-6697-5471]
dc.contributor.orcidCarranza Isaza, Hernán [0000-0002-3593-7405]
dc.contributor.orcidVargas Báez, Carlos Alberto [0000-0002-6076-8260]
dc.contributor.orcidRojas Puentes, Leonardo [0000-0002-7865-5424]
dc.contributor.orcidRodríguez Ariza, July Katherine [0000-0003-1168-595X]
dc.date.accessioned2020-04-24T17:12:04Z
dc.date.available2020-04-24T17:12:04Z
dc.date.issued2016
dc.description.abstractenglishBackground: Germline alterations in the proapoptotic protein Bcl-2-like 11 (BIM) can have a crucial role in diverse tumors. To determine the clinical utility of detecting BIM deletion polymorphisms (par4226 bp/ par363 bp) in EGFR positive non-small-cell lung cancer (NSCLC) we examined the outcomes of patients with and without BIM alterations. Results: BIM deletion was present in 14 patients (15.7%). There were no significant differences between patients with and without BIM-del in clinical characteristics or EGFR mutation type; however, those with BIM-del had a worse overall response rate (ORR) to erlotinib (42.9% vs. 73.3% in patients without BIM-del; p=0.024) as well as a significantly shorter progression-free survival (PFS) (10.8 BIM-del+ vs. 21.7 months for patients without BIM-del; p=0.029) and overall survival (OS) (15.5 BIM-del+ vs. 34.0 months for patients without BIM-del; p=0.035). Multivariate Cox regression analysis showed that BIM-del+ was an independent indicator of shorter PFS (HR 3.0; 95%CI 1.2-7.6; p=0.01) and OS (HR 3.4; 95%CI 1.4-8.3; p=0.006). Methods: We studied 89 NSCLC Hispanic patients with EGFR mutation who were treated with erlotinib between January 2009 and November 2014. BIM deletion polymorphisms (BIM-del) was analyzed by PCR in formalin-fixed paraffin-embedded (FFPE) tissues of tumor biopsies. We retrospectively analyzed clinical characteristics, response rate, toxicity, and outcomes among patients with and without BIM-del. Conclusions: The incidence of BIM-del found in Hispanic patients is similar to that previously described in Asia. This alteration is associated with a poor clinical response to erlotinib and represents an independent prognostic factor for patients who had NSCLC with an EGFR mutation.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.18632/oncotarget.12112
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1949-2553
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlrepourl:https://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/2374
dc.language.isoeng
dc.publisherImpact Journalsspa
dc.publisher.journalOncotargetspa
dc.relation.ispartofseriesOncotarget, 1949-2553. Vol, 7, Nro, 42. 2016.spa
dc.relation.urihttps://www.oncotarget.com/article/12112/text/
dc.rightsAttribution 4.0 International*
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf60
dc.rights.creativecommons2016
dc.rights.localAcceso abiertospa
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subject.decsNeoplasias pulmonaresspa
dc.subject.decsProteína 11 similar a Bcl2spa
dc.subject.decsGenes erbB-1spa
dc.subject.keywordsBIM deletionspa
dc.subject.keywordsNon-small cell lung cancerspa
dc.subject.keywordsEGFR mutationspa
dc.subject.keywordsSurvivalspa
dc.titleBIM deletion polymorphisms in hispanic patients with non-small cell lung cancer carriers of EGFR mutationsspa
dc.title.translatedBIM deletion polymorphisms in hispanic patients with non-small cell lung cancer carriers of EGFR mutations
dc.typearticlespa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localartículospa

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Cardona A.F., Rojas L., Wills B., Arrieta O., Carranza H., Vargas C., Otero J., Corrales-Rodriguez L., Martín C., Reguart N., Archila P., Rodríguez J., Cuello M., Ortíz C., Franco S., Rolfo C., Rosell R._2016.pdf
Tamaño:
2.7 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos